Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

manilatimes.net · 2026-10-25

Media Release

TickrTrends take: Genmab's updated Phase 2 data for petosemtamab in metastatic colorectal cancer represents a clinical development milestone that could influence investor assessment of the company's pipeline value. Given TickrTrends' current Overvalued designation for the Healthcare sector company, investors should monitor whether positive clinical efficacy data can justify the present valuation or whether market enthusiasm will prove temporary relative to the stock's current price level. The clinical progress in this indication adds a tangible near-term catalyst, though the valuation context suggests the market may already be pricing in optimistic outcomes.

Read the full story at manilatimes.net →